What is the clinical evidence from this study?

Study design: Review. Population: Autoantibody-associated congenital heart block (CHB).

What does this research mean for the field?

Antibody-related congenital heart block is a multifactorial condition that necessitates comprehensive management, including the use of fetal echocardiography for timely diagnosis, prenatal counseling, and preventive medication. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 11, 2025Open Access

Effects of maternal anti-Ro/La antibodies on fetal atrioventricular conduction evaluated with echocardiography: a state-of-the-art review

Key Result

Maternal anti-Ro/SSA and anti-La/SSB antibodies increase the risk of fetal congenital heart block, necessitating comprehensive prenatal counseling, fetal echocardiography monitoring, and potential preventive medication management.

Structured PICO

Population

Pregnant women with anti-Ro/SSA and anti-La/SSB antibodies and their fetuses at risk for congenital heart block (CHB)

Intervention

Fetal echocardiography (including M-mode, pulsed-wave Doppler, and tissue Doppler) and in-utero treatments (e.g., fluorinated corticosteroids, IVIG)

Fetal echocardiography is a critical tool for the early diagnosis and monitoring of autoantibody-associated congenital heart block, enabling timely in-utero interventions.

Limitations

The low incidence rate of CHB, combined with the variable efficacy and potential risks associated with pharmacologic interventions, has resulted in ongoing controversy regarding optimal treatment strategies.
The optimal timing, dosage, and duration of preventive treatments require further investigation through well-designed clinical studies.

Abstract

Anti-Ro/SSA and La/SSB antibodies can cross the placenta, affecting fetal cardiac development and leading to congenital heart block (CHB), a condition characterized by rapid progression, high mortality, and poor prognosis, emphasizing the importance of timely diagnosis and treatment. Fetal echocardiography is a critical diagnostic tool for CHB. With advancements in medicine and shifting health perspectives, the incidence, diagnostic approaches, and treatment methods for CHB are evolving. This review examines the impact of maternal antibodies on offspring, including their pathogenic mechanisms and other influencing factors such as antibody levels and maternal conditions. It also evaluates the application of fetal echocardiography in diagnosing CHB, covering techniques like M-mode, tissue Doppler, and spectral Doppler, and investigates antibody-associated CHB incidence. In addition, the review discusses management strategies for anti-Ro/SSA and anti-La/SSB positive pregnancies, including fetal in-utero treatment, preventive therapy for mothers, and other pharmacologic interventions. The findings highlight that antibody-related CHB is multifactorial, necessitating comprehensive consideration of influencing factors, prenatal counseling, and preventive medication management.

Mark Helpful

Bookmark

Relay

View Full Paper